Latest Theragenics Corp. (TGX) Headlines Intern
Post# of 2
Posted On: 03/14/2014 9:17:30 AM
Latest Theragenics Corp. (TGX) Headlines
Internal Beam & Systemic Radiation Therapy Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2017
M2 - Wed Mar 12, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7wqw3/internal_beam_and) has announced the addition of the "Internal Beam & Systemic Radiation Therapy Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2017" report to their offering. Rising cancer cases have made radiotherapy a standard procedure for oncology treatment. With a prominent rise in their GDP, emerging nations act as the future growth opportunities for the global radiotherapy market. Internal radiation therapy or brachytherapy is one of the oldest techniques for the treatment of cancerous tumors. As per the procedures, this process is categorized into permanent and temporary procedures where low dose rate and high dose rate brachytherapy are applied respectively. This report comprises of a holistic analysis of the market in terms of forces affecting the market. Its sub-components/forces include bargaining power of suppliers, bargaining power of buyers, threat of substitutes, threat of new entrants and competitive rivalry. The study analyzes the market for segments such as brachytherapy seeds, applicators and afterloaders and electronic brachytherapy along with their applications that include Prostate cancer, gynecological cancer, breast cancer, cervical cancer, penile cancer, lung cancer, head and neck cancer and esophageal cancer. The study also analyzes four regions namely, North America, Europe, Asia-Pacific and Rest of the World for the Internal Beam Radiation Devices Market. The report elucidates several dynamics of the market such as the drivers, inhibitors, and opportunities that are illustrated throughout the report. It provides current and future outlook for the market on a global level as well as a focused view on independent sub-segments within the market. The report also profiles key market players Accuray Inc., Angiodynamics Inc., Boston Scientific Corporation, C.R. Bard, Cardinal Health Inc., Covidien PLC, GE Healthcare, Siemens Healthcare, Theragenics Corporation and others. The study provides a market share analysis for the year 2012 with respect to key players and also provides recent developments for all profiled companies. Key Topics Covered - Introduction to the Report - Market Synopsis - Market Dynamics - Products Market Size & Forecast - Global Internal Beam Radiation Therapy Devices - Products Market Size & Forecast - Global Systemic Radiation Therapy Devices - Applications Market Size & Forecast - Global Internal Beam Radiation and Systemic Therapy Devices - Technology Market Size & Forecast - Global Internal Beam Radiation Therapy Devices - Geography Market Size & Forecast - Global Internal Beam & Systemic Radiation Therapy Devices - Competitive Scenario: Key Players - Company Profiles Companies Mentioned - Boston Scientific - C.R. Bard - Eckert & Ziegler BEBIG - Elekta AB - GE Healthcare - IBA - Nordion - Theragenics - Varian Medical Systems For more information visit http://www.researchandmarkets.com/research/t7...l_beam_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Ablation Technologies Market 2012-2016: Major Cancer Diseases that Use Ablation Technology Devices are Discussed in Detail
M2 - Mon Mar 10, 11:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5z78kx/global_ablation) has announced the addition of the "Global Ablation Technologies Market 2012-2016" report to their offering. The analysts forecast the Global Ablation Technologies market to grow at a CAGR of 10.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased demand for minimally invasive surgical procedures. The Global Ablation Technologies market has also been witnessing the trend of miniaturizing medical devices. However, the varying regulations for medical devices could pose a challenge to the growth of this market. Ablation technology devices are used for various clinical applications and Cancer therapy, and accounted for the largest segment of the Global Ablation Technologies market. The key vendors dominating this market space include Boston Scientific Corp., Medtronic Inc., St.Jude Medical Inc., and Varian Medical Systems Inc. The other vendors mentioned in the report are Accuray Inc., Alcon Laboratories Inc., AngioDynamics Inc., Arthrocare Corp., Atricure Inc., ATS Medical Inc., Biosense Webster Inc., BSD Medical Corporation, C.R. Bard Inc., Candela Corp., CardioGenesis Corp., CermaVEIN SAS, ConMed Corporation, Covidien plc, EDAP TMS S.A., Elekta AB, Endo Health Solutions Inc., Galil Medical Ltd., HealthTronics Inc., Hologic Inc., Idoman Ltd., Maquet Holding GmbH and Co. KG (Gentinge AB group), Microsulis Medical Ltd, Misonix Inc., nContact Surgical Inc., Olympus Corp., Relievant Medsystems, Rhythmia Medical Inc., Smith and Nephew plc, Solta Medical Inc., Syneron Medical Ltd., TheraGenics Corp., Urologix Inc., VNUS Medical Technologies Inc., and Zeltiq Aesthetics Inc. Commenting on the report, an analyst from the Healthcare team said: One of the upcoming trends in the Global Ablation Technology market is the rapid advancements in technology using ablation technology devices. Although the market for ablation technology devices is at a mature stage, the level of technology is still at a nascent stage; more devices with cutting-edge technology are expected to be introduced in the near future. Recently, laser ablation devices have been introduced to perform precise ablation of body tissue; these devices run on a laser energy transmission mechanism using fiber optics. This kind of device is used in transmyocardial revascularization and angioplasty. Another major advancement is the usage of catheter ablation for atrial fibrillation, which is commonly used to control tachy-arrhythmia. Thus, the rapid advancement in technology is an emerging trend that has a strong impact on the market. For more information visit http://www.researchandmarkets.com/research/5z...l_ablation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Brachytherapy Devices Worldwide Market Report 2013-2016
M2 - Fri Nov 01, 6:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52pl6c/global) has announced the addition of the "Brachytherapy Devices Worldwide Market Report 2013-2016" report to their offering. Analysts forecast the brachytherapy devices market to grow at a CAGR of 2.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant increase in the number of cancer patients worldwide. The Global Brachytherapy Devices market has also been witnessing a significant increase in the number of acquisitions. However, alternatives for cancer treatment could pose a challenge to the growth of this market. The report, Brachytherapy Devices Worldwide Market Report 2013-2016, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Brachytherapy Devices market landscape and its growth prospects in the coming years. Key questions answered in this report: - What will the market size be in 2016 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? - You can request one free hour of analyst time when you purchase this report. Details provided within the report. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Coverage 4. Market Landscape 5. Geographical Segmentation 6. Key Leading Countries 7. Rate of Incidence and Prevalence 8. Vendor Landscape 9. Buying Criteria 10. Market Growth Drivers 11. Drivers and Their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Key Vendor Analysis 16. Other Reports in this Series Companies Mentioned - Boston Scientific - C.R. Bard - CIVCO Medical Instruments - CONMED - Cook Medical - Eckert & Ziegler BEBIG - Elekta AB - GE Healthcare - Gammex - Huiheng Medical - Olympus - Theragenics - Varian Medical Systems For more information visit http://www.researchandmarkets.com/research/52pl6c/global
Theragenics Corporation concludes merger with and into Juniper Acquisition Corporation
M2 - Wed Oct 30, 7:38AM CDT
Medical device company Theragenics Corporation (NYSE:TGX) reported on Tuesday the completion of its merger with Juniper Acquisition Corporation, an affiliate of Juniper Investment Company LLC.
Theragenics Announces Completion of Merger with Juniper
Business Wire - Tue Oct 29, 12:55PM CDT
Theragenics Corporation(R) (NYSE: TGX) (the "Company"), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that it completed the merger with Juniper Acquisition Corporation, an affiliate of Juniper Investment Company, LLC ("Juniper"). As a result of the merger, each outstanding share of common stock of the Company (other than shares held by Juniper Acquisition Corporation) was converted into the right to receive $2.20 per share in cash, and the Company has become a wholly owned subsidiary of an affiliate of Juniper.
Theragenics Announces Stockholder Approval of Merger Agreement with Juniper
Business Wire - Thu Oct 17, 8:27AM CDT
Theragenics Corporation(R) (NYSE: TGX) (the "Company"), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that the stockholders of the Company voted to approve the previously announced merger agreement providing for a newly formed affiliate of Juniper Investment Company, LLC to acquire all of the outstanding common stock of the Company for $2.20 per share in cash.
OTC Daily Alert Stock Watch - Theragenics Corporation, (NYSE: TGX)
WorldStockWire - Wed Oct 16, 2:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
NYSE stocks posting largest volume increases
AP - Mon Sep 16, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
Theragenics Announces Expiration of the "Go-Shop" Period and Sets Date for Stockholders Meeting to Vote on Merger
Business Wire - Mon Sep 09, 7:14AM CDT
Theragenics Corporation(R) (NYSE: TGX) (the "Company"), a medical device company serving the surgical products and prostate cancer treatment markets, announced today the expiration of the 35-day "go-shop" period pursuant to the terms of the previously announced merger agreement providing for a newly formed affiliate of Juniper Investment Company, LLC to acquire all of the outstanding common stock of the Company for $2.20 per share in cash.
New Survey Reveals Men Are at Odds with U.S. Preventive Services Task Force Recommendations Against PSA Test
Business Wire - Mon Aug 26, 6:42AM CDT
A new survey suggests that men may not always know just what the doctor has ordered when it comes to PSA screening. In a survey of 1,539 men, 80 percent were unaware that the U.S. Preventive Services Task Force has recommended against screening for prostate cancer in healthy men. "Because many men are unaware of the Task Force guidelines, they may mistakenly assume that a PSA test is being conducted as part of the overall lab work typically ordered during a physical examination," says Mark Scholz, M.D., a medical oncologist and executive director of the non-profit Prostate Cancer Research Institute. "The lack of awareness may have direct consequences on the future of their health and certainly limits their opportunity for an open and informed conversation with their physician."
Internal Beam & Systemic Radiation Therapy Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2017
M2 - Wed Mar 12, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7wqw3/internal_beam_and) has announced the addition of the "Internal Beam & Systemic Radiation Therapy Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2017" report to their offering. Rising cancer cases have made radiotherapy a standard procedure for oncology treatment. With a prominent rise in their GDP, emerging nations act as the future growth opportunities for the global radiotherapy market. Internal radiation therapy or brachytherapy is one of the oldest techniques for the treatment of cancerous tumors. As per the procedures, this process is categorized into permanent and temporary procedures where low dose rate and high dose rate brachytherapy are applied respectively. This report comprises of a holistic analysis of the market in terms of forces affecting the market. Its sub-components/forces include bargaining power of suppliers, bargaining power of buyers, threat of substitutes, threat of new entrants and competitive rivalry. The study analyzes the market for segments such as brachytherapy seeds, applicators and afterloaders and electronic brachytherapy along with their applications that include Prostate cancer, gynecological cancer, breast cancer, cervical cancer, penile cancer, lung cancer, head and neck cancer and esophageal cancer. The study also analyzes four regions namely, North America, Europe, Asia-Pacific and Rest of the World for the Internal Beam Radiation Devices Market. The report elucidates several dynamics of the market such as the drivers, inhibitors, and opportunities that are illustrated throughout the report. It provides current and future outlook for the market on a global level as well as a focused view on independent sub-segments within the market. The report also profiles key market players Accuray Inc., Angiodynamics Inc., Boston Scientific Corporation, C.R. Bard, Cardinal Health Inc., Covidien PLC, GE Healthcare, Siemens Healthcare, Theragenics Corporation and others. The study provides a market share analysis for the year 2012 with respect to key players and also provides recent developments for all profiled companies. Key Topics Covered - Introduction to the Report - Market Synopsis - Market Dynamics - Products Market Size & Forecast - Global Internal Beam Radiation Therapy Devices - Products Market Size & Forecast - Global Systemic Radiation Therapy Devices - Applications Market Size & Forecast - Global Internal Beam Radiation and Systemic Therapy Devices - Technology Market Size & Forecast - Global Internal Beam Radiation Therapy Devices - Geography Market Size & Forecast - Global Internal Beam & Systemic Radiation Therapy Devices - Competitive Scenario: Key Players - Company Profiles Companies Mentioned - Boston Scientific - C.R. Bard - Eckert & Ziegler BEBIG - Elekta AB - GE Healthcare - IBA - Nordion - Theragenics - Varian Medical Systems For more information visit http://www.researchandmarkets.com/research/t7...l_beam_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Ablation Technologies Market 2012-2016: Major Cancer Diseases that Use Ablation Technology Devices are Discussed in Detail
M2 - Mon Mar 10, 11:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5z78kx/global_ablation) has announced the addition of the "Global Ablation Technologies Market 2012-2016" report to their offering. The analysts forecast the Global Ablation Technologies market to grow at a CAGR of 10.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased demand for minimally invasive surgical procedures. The Global Ablation Technologies market has also been witnessing the trend of miniaturizing medical devices. However, the varying regulations for medical devices could pose a challenge to the growth of this market. Ablation technology devices are used for various clinical applications and Cancer therapy, and accounted for the largest segment of the Global Ablation Technologies market. The key vendors dominating this market space include Boston Scientific Corp., Medtronic Inc., St.Jude Medical Inc., and Varian Medical Systems Inc. The other vendors mentioned in the report are Accuray Inc., Alcon Laboratories Inc., AngioDynamics Inc., Arthrocare Corp., Atricure Inc., ATS Medical Inc., Biosense Webster Inc., BSD Medical Corporation, C.R. Bard Inc., Candela Corp., CardioGenesis Corp., CermaVEIN SAS, ConMed Corporation, Covidien plc, EDAP TMS S.A., Elekta AB, Endo Health Solutions Inc., Galil Medical Ltd., HealthTronics Inc., Hologic Inc., Idoman Ltd., Maquet Holding GmbH and Co. KG (Gentinge AB group), Microsulis Medical Ltd, Misonix Inc., nContact Surgical Inc., Olympus Corp., Relievant Medsystems, Rhythmia Medical Inc., Smith and Nephew plc, Solta Medical Inc., Syneron Medical Ltd., TheraGenics Corp., Urologix Inc., VNUS Medical Technologies Inc., and Zeltiq Aesthetics Inc. Commenting on the report, an analyst from the Healthcare team said: One of the upcoming trends in the Global Ablation Technology market is the rapid advancements in technology using ablation technology devices. Although the market for ablation technology devices is at a mature stage, the level of technology is still at a nascent stage; more devices with cutting-edge technology are expected to be introduced in the near future. Recently, laser ablation devices have been introduced to perform precise ablation of body tissue; these devices run on a laser energy transmission mechanism using fiber optics. This kind of device is used in transmyocardial revascularization and angioplasty. Another major advancement is the usage of catheter ablation for atrial fibrillation, which is commonly used to control tachy-arrhythmia. Thus, the rapid advancement in technology is an emerging trend that has a strong impact on the market. For more information visit http://www.researchandmarkets.com/research/5z...l_ablation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Brachytherapy Devices Worldwide Market Report 2013-2016
M2 - Fri Nov 01, 6:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52pl6c/global) has announced the addition of the "Brachytherapy Devices Worldwide Market Report 2013-2016" report to their offering. Analysts forecast the brachytherapy devices market to grow at a CAGR of 2.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant increase in the number of cancer patients worldwide. The Global Brachytherapy Devices market has also been witnessing a significant increase in the number of acquisitions. However, alternatives for cancer treatment could pose a challenge to the growth of this market. The report, Brachytherapy Devices Worldwide Market Report 2013-2016, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Brachytherapy Devices market landscape and its growth prospects in the coming years. Key questions answered in this report: - What will the market size be in 2016 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? - You can request one free hour of analyst time when you purchase this report. Details provided within the report. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Coverage 4. Market Landscape 5. Geographical Segmentation 6. Key Leading Countries 7. Rate of Incidence and Prevalence 8. Vendor Landscape 9. Buying Criteria 10. Market Growth Drivers 11. Drivers and Their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Key Vendor Analysis 16. Other Reports in this Series Companies Mentioned - Boston Scientific - C.R. Bard - CIVCO Medical Instruments - CONMED - Cook Medical - Eckert & Ziegler BEBIG - Elekta AB - GE Healthcare - Gammex - Huiheng Medical - Olympus - Theragenics - Varian Medical Systems For more information visit http://www.researchandmarkets.com/research/52pl6c/global
Theragenics Corporation concludes merger with and into Juniper Acquisition Corporation
M2 - Wed Oct 30, 7:38AM CDT
Medical device company Theragenics Corporation (NYSE:TGX) reported on Tuesday the completion of its merger with Juniper Acquisition Corporation, an affiliate of Juniper Investment Company LLC.
Theragenics Announces Completion of Merger with Juniper
Business Wire - Tue Oct 29, 12:55PM CDT
Theragenics Corporation(R) (NYSE: TGX) (the "Company"), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that it completed the merger with Juniper Acquisition Corporation, an affiliate of Juniper Investment Company, LLC ("Juniper"). As a result of the merger, each outstanding share of common stock of the Company (other than shares held by Juniper Acquisition Corporation) was converted into the right to receive $2.20 per share in cash, and the Company has become a wholly owned subsidiary of an affiliate of Juniper.
Theragenics Announces Stockholder Approval of Merger Agreement with Juniper
Business Wire - Thu Oct 17, 8:27AM CDT
Theragenics Corporation(R) (NYSE: TGX) (the "Company"), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that the stockholders of the Company voted to approve the previously announced merger agreement providing for a newly formed affiliate of Juniper Investment Company, LLC to acquire all of the outstanding common stock of the Company for $2.20 per share in cash.
OTC Daily Alert Stock Watch - Theragenics Corporation, (NYSE: TGX)
WorldStockWire - Wed Oct 16, 2:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
NYSE stocks posting largest volume increases
AP - Mon Sep 16, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
Theragenics Announces Expiration of the "Go-Shop" Period and Sets Date for Stockholders Meeting to Vote on Merger
Business Wire - Mon Sep 09, 7:14AM CDT
Theragenics Corporation(R) (NYSE: TGX) (the "Company"), a medical device company serving the surgical products and prostate cancer treatment markets, announced today the expiration of the 35-day "go-shop" period pursuant to the terms of the previously announced merger agreement providing for a newly formed affiliate of Juniper Investment Company, LLC to acquire all of the outstanding common stock of the Company for $2.20 per share in cash.
New Survey Reveals Men Are at Odds with U.S. Preventive Services Task Force Recommendations Against PSA Test
Business Wire - Mon Aug 26, 6:42AM CDT
A new survey suggests that men may not always know just what the doctor has ordered when it comes to PSA screening. In a survey of 1,539 men, 80 percent were unaware that the U.S. Preventive Services Task Force has recommended against screening for prostate cancer in healthy men. "Because many men are unaware of the Task Force guidelines, they may mistakenly assume that a PSA test is being conducted as part of the overall lab work typically ordered during a physical examination," says Mark Scholz, M.D., a medical oncologist and executive director of the non-profit Prostate Cancer Research Institute. "The lack of awareness may have direct consequences on the future of their health and certainly limits their opportunity for an open and informed conversation with their physician."
(0)
(0)Theragenics Corp. (TGX) Stock Research Links
Scroll down for more posts ▼